Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden by Srivastava, T. et al.
Cost-effectiveness of Pembrolizumab as Second-line Therapy
for the Treatment of Locally Advanced or Metastatic Urothelial
Carcinoma in Sweden
Tushar Srivastava a, Vimalanand S. Prabhu b, Haojie Li b, Ruifeng Xu b, Natalie Zarabi c,
Yichen Zhong b,*, James M. Pellissier b, Rodolfo F. Perini b, Ronald de Wit d, Ronac Mamtani e
aComplete HEOR Solutions, North Wales, PA, USA; bMerck & Co, Inc., Kenilworth, NJ, USA; cMerck Sharp & Dohme, Stockholm, Sweden; d Erasmus MC Cancer
Institute, Rotterdam, The Netherlands; eAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
E U R O P E A N U R O L O G Y O N C O L O G Y 3 ( 2 0 2 0 ) 6 6 3 – 6 7 0
ava i lable at www.sc iencedirect .com
journa l homepage: euoncology.europeanurology .com
Article info
Article history:
Accepted September 25, 2018
Associate Editor:
Ashish Kamat
Keywords:
Bladder cancer
Cost-effectiveness
Immunotherapy
Pembrolizumab
Urothelial carcinoma
Abstract
Background: Urothelial carcinoma (UC) is the most common subtype of bladder
cancer. The randomized phase 3 KEYNOTE-045 trial showed that pembrolizumab,
used as second-line therapy significantly prolonged overall survival with fewer
treatment-related adverse events than chemotherapy for advanced UC. Pembro-
lizumab has been approved by the European Medicines Agency for the treatment of
locally advanced or metastatic UC in adults who have received platinum-contain-
ing chemotherapy. Many European countries use cost-effectiveness analysis to
inform reimbursement decisions.
Objective: To assess the cost-effectiveness of pembrolizumab as second-line ther-
apy for the treatment of advanced UC from a Swedish health care perspective.
Design, setting, and participants: We developed a partitioned-survival model to
assess the costs and effectiveness of pembrolizumab compared with vinflunine
(base case), paclitaxel, or docetaxel monotherapy in patients with advanced UC
over a 15-yr time horizon. We obtained Kaplan-Meier estimates for survival end-
points, adverse events, and utility data from KEYNOTE-045.
Outcome measurements and statistical analysis: We performed parametric extra-
polations to estimate overall and progression-free survival beyond the clinical trial
period. Swedish costs and utility weights were used to estimate total costs, quality-
adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We
performed deterministic and probabilistic sensitivity analyses to assess the ro-
bustness of the model results.
Results and limitations: In the base-case analysis, pembrolizumab resulted in a
mean survival gain of 1.66 years (1.38 QALYs) at an incremental cost of s69 852 and
an ICER of s50 529/QALY gained versus vinflunine monotherapy. ICERs for other
chemotherapies were s81 356/QALY for pembrolizumab versus paclitaxel or doc-
etaxel monotherapy, and s71 924/QALY for pembrolizumab versus paclitaxel,
docetaxel, or vinflunine monotherapy. Long-term follow-up from KEYNOTE-045 ar
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Conclusions: The results indicate that pembrolizumab improves survival, increases
QALYs, and is cost-effective as second-line therapy at a willingness-to-pay thresh-
old of s100 000/QALY for the treatment of advanced UC.
Patient summary: To date, pembrolizumab is the only treatment associated with a
significant overall survival benefit compared with chemotherapy in a randomized
controlled trial as second-line therapy for advanced urothelial carcinoma. Our trial-
based cost-effectiveness analysis suggests that pembrolizumab is a cost-effective
option over chemotherapy in patients with advanced urothelial carcinoma after
platinum-based therapy in Sweden.
© 2018 Merck Sharp & Dohme Corp and The Authors. Published Elsevier B.V. on behalf of
European Association of Urology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Bladder cancer (BC) is the ninth most common cancer
worldwide [1] and results in significant mortality, morbidi-
ty, and costs [2,3]. The vast majority of BC cases (90%) are
urothelial carcinoma and occur in developed countries,
with the highest incidence in North America and Europe
[1,4]. In 2015, the incidence in Sweden was approximately
2700 patients with a median age of 73 yr [5,6]. In 2012, the
total estimated cost of BC was s4.9 billion in Europe, with
s2.9 billion in direct costs and s2.0 billion in indirect costs
associated with productivity losses due to mortality and
morbidity [7,8]. In Sweden, BC accounted for s136.61
million in total costs in 2012 [7]. Intense follow-up, high
recurrence rates, and preoperative and postoperative
complications were the key contributors to this economic
burden [7].
In patients with locally advanced or metastatic urothelial
carcinoma, platinum-based combination therapies are recom-
mended as the first-line standard of care (SoC) [9]. Most
patients experience relapse following first-line therapy (40–
70%) and historically were faced with a choice between
receiving second-line toxic chemotherapies with limited
efficacy (vinflunine or a taxane) or palliative symptom relief
with noncurative intent [10]. Pembrolizumab, a monoclonal
antibody against PD-1, is the first immunotherapy to demon-
strate superior overall survival (OS) compared with chemo-
therapy in patients with advanced urothelial carcinoma after
failure of platinum-based therapy [11]. The clinical efficacy of
pembrolizumab in advanced urothelial carcinoma after failure
of platinum-based therapy was established in KEYNOTE-045
(NCT02256436), a phase 3 multicenter global randomized
clinical trial with chemotherapy comparators that included
paclitaxel, docetaxel, and vinflunine monotherapy. The trial
demonstrated improvements in median OS when compared to
chemotherapy (10.3 mo in the pembrolizumab arm compared
with 7.4 mo in the chemotherapy arm) [11]. On the basis of
KEYNOTE-045 data, pembrolizumab was approved in Europe
for the treatment of locally advanced or metastatic urothelial
carcinoma in adults who have previously received platinum-
containing chemotherapy [12].
In many European countries, cost-effectiveness evalua-
tions play a critical role in the decision to reimburse health
care providers for pharmaceuticals. In the Swedish health
care system, the Dental and Pharmaceutical Benefits Agencyand the New Therapies Council recently recommended
pembrolizumab for patients with advanced urothelial
carcinoma who have previously received platinum-contain-
ing chemotherapy on the basis of ethical considerations and
health economics evaluation of this treatment [13].
The objective of the current analysis was to evaluate the
cost-effectiveness of pembrolizumab compared with che-
motherapy as second-line therapy for the treatment of
locally-advanced or metastatic urothelial carcinoma at a
willingness-to-pay threshold of s100 000 per quality-
adjusted life year (QALY) from a Swedish health care
perspective [14].
2. Patients and methods
2.1. Patient population
The target population was patients with advanced urothelial carcinoma
who had received platinum-based chemotherapy and experienced
disease progression during or following that chemotherapy [11].
2.2. Comparators
For the base-case analysis, costs and effects for pembrolizumab were
compared with those for vinflunine, the only therapy recommended as
second-line treatment for advanced urothelial carcinoma according to
Swedish guidelines. Two additional analyses were considered: pem-
brolizumab compared with taxanes (paclitaxel or docetaxel mono-
therapy), and pembrolizumab compared with paclitaxel, docetaxel, or
vinflunine monotherapy (the control arm in KEYNOTE-045). The dose
and frequency considered were as for KEYNOTE-045: pembrolizumab,
200 mg; vinflunine, 320 mg/m2; paclitaxel, 175 mg/m2; and docetaxel,
75 mg/m2; each treatment was administered intravenously once every
3 week.
Costs and effectiveness were evaluated for pembrolizumab and
comparators in the target patient population using data from KEYNOTE-
045. Patient characteristics in the pembrolizumab and comparator arms
were comparable.
2.3. Model structure
A partitioned-survival model was developed in Excel 2010 (Microsoft,
Redmond, WA, USA) to project the costs and effects for each regimen in the
target population [15]. The model includes three health states (Fig. 1):
progression-free, progressive disease, and death. The progression-free
health state includes patients who have progressed on first-line treatment
with platinum-based chemotherapy and have begun second-line treatment.
Fig. 1 – Diagram of transitions in the partitioned survival model used to
estimate health economics outcomes.
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experience disease progression. Progression is defined in line with
KEYNOTE-045 and assessed by blinded independent central review in
accordance with Response Evaluation Criteria in Solid Tumors v1.1. Patients
mayalso die in either the progression-free or progressive disease health state
(transition to the death state).
The model estimates the probability of being in each of the three
health states at the end of each week. Survival estimates from the
progression-free survival (PFS) curve provide the probability a patient is
in the progression-free health state. The survival estimates from the OS
distribution represent the patient’s likelihood of being dead or alive at
each particular time point. Finally, the difference between the OS and PFS
curves yields the probability that the patient is in the progressive disease
health state. Kaplan-Meier survival curves based on clinical trial
endpoints in KEYNOTE-045 were used for time points during the trialTable 1 – Model inputs.
Pembrolizumab 
Patient characteristics
Mean body weight, kg (SD) 73.58 (17.23) 
Mean BSA, m2 (SD) 1.85 (0.25) 
Cost inputs
Drug cost (s)
50-mg vial 1688 
250-mg vial 
Administration (s/administration) 269 
Disease management
PF (s/week) 92 
Progressive disease (s/week) 215 
Subsequent treatment (s/week) 0 
Terminal care (month before death) 7356 
Utilities Mean EQ-5
Pembrolizumab 
PF with grade 3 AE 0.798 (0.772–0.823) 
PF without grade 3 AE 0.865 (0.857–0.874) 
Disutility due to grade 3 AE (by subtraction) 0.067 
Progressive disease 0.821 (0.808–0.834) 
AE = adverse event; BSA = body surface area; HCRU = health care resource utiliza
a EQ-5D utility based on all treated patients as per the Swedish algorithm.period, while parametric survival functions were developed to project
PFS and OS beyond the trial period (Table 1). Life expectancy data from
Swedish life tables were also considered to account for age-specific all-
cause mortality. The model assumed that the cost and health benefits
accrued at weekly-spaced discrete time points over the time horizon of
15 yr.
2.4. Clinical and utility inputs
Clinical inputs such as adverse event (AE) incidence rates, weight, body
surface-area distributions, and utility inputs were drawn from KEY-
NOTE-045 with a cutoff date of January 18, 2017. We used utility values
for the progression-free and progressive disease health states, and the
disutility associated with grade 3 AEs using EQ-5D survey responses
from KEYNOTE-045 and Swedish utility weights [16,17].
2.5. Cost inputs
The costs for resources utilized by patients were expressed in 2018 euros
(s) [18]. We obtained drug acquisition costs from Pharmacy Heart
(Apotek Hjärtat), a national Swedish pharmacy. We also considered drug
administration and diagnostic tests in our model [19]. We modeled the
cost for subsequent therapy on the Swedish clinical input whereby 10% of
patients in the vinflunine arm were subsequently administered
gemcitabine and carboplatin for an average of 20 week [19]. We
included in our analysis the disease management costs incurred while in
the progression-free and progressive disease health states, hospice and
other costs associated with the last month before death, and AE-related
costs (Table 1).
2.6. Statistical analysis
Kaplan-Meier survival curves for PFS, OS, and time-on-treatment (ToT)
were obtained from KEYNOTE-045. Because 13.3% of the patients in the
vinflunine arm received immunotherapy after discontinuation, it is likely
that OS was overestimated in the control arm [20]. To adjust for this bias,
we used the prespecified rank-preserving structural-failure time (RPSFT)Vinflunine Data source
73.58 (17.23) KEYNOTE-045
1.85 (0.25) KEYNOTE-045
257 [27]
1252
269 [18]
92 Weekly HCRU and unit costs
215 Weekly HCRU and unit costs
714 [19]
7356 [28]
D utility (95% confidence interval) a Data source
Vinflunine Pooled
0.822 (0.796–0.848) 0.806 (0.787–0.825) KEYNOTE-045
0.830 (0.812–0.848) 0.859 (0.851–0.866) KEYNOTE-045
0.008 0.053 KEYNOTE-045
0.764 (0.736–0.792) 0.813 (0.801–0.824) KEYNOTE-045
tion; PF = progression-free; SD = standard deviation.
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feasible for the base-case comparator owing to the small sample size.
Two-stage adjustment was applied as a better method in addressing the
OS bias than the RPSFT method for comparison of pembrolizumab with
paclitaxel/docetaxel/vinflunine and with paclitaxel/docetaxel in the
sensitivity analysis [21].
Survival projections beyond the trial period were developed to
estimate long-term OS and PFS in accordance with National Institute for
Health and Care Excellence (NICE) guidelines [22]. We applied a
piecewise extrapolation technique to account for structural differences
observed in the initial parts of the Kaplan-Meier curves from KEYNOTE-
045. We divided the time horizon into two parts, with the cutoff point
determined according to the statistical method recommended by NICE,
for both treatment arms [22]. The first part uses the Kaplan-Meier
estimates for OS and PFS, while the subsequent part provides
extrapolation based on the best fit among exponential, Weibull,
Gompertz, log-logistic, log-normal, and generalized gamma parametric
distributions. We used visual inspection of the Kaplan-Meier curves,
goodness-of-fit statistics, and clinical plausibility to determine the
parametric distribution with the best fit.
Similar to the approach for OS and PFS, ToTs for pembrolizumab and
comparator arms were explicitly modeled as an outcome and estimated
on the basis of KEYNOTE-045 data. We extrapolated and modeled ToT
data using one-piece parametric curves (Supplementary material).
2.7. Outputs
We estimated the proportion of patients in each health state for each
cycle over 15 yr by modeling OS and PFS. Costs and utility weights were
subsequently assigned to the health states. We summed the costs and
utilities over the cycles to estimate the projected direct medical costs,
total costs, life years, and QALYs for pembrolizumab and the selected
comparator. The incremental costs and QALYs were then used to
estimate the incremental cost-effectiveness ratio (ICER; incremental cost
per QALY gained). We used an annual discount rate of 3% to determine
the present value of costs and health outcomes in this economic
evaluation.
We depicted one-way sensitivity analyses using a tornado diagram to
examine the impact of changes in each of the input parameters on the
results. We conducted a probabilistic sensitivity analysis using a second-
order Monte Carlo simulation with 1000 iterations to examine the
robustness of the model outputs and the uncertainty of all parameters
taken together.
3. Results
3.1. Base-case results
We considered Kaplan-Meier curves before week 15 for PFS
and week 32 for OS and used the best-fitting parametric
distributions, which were a log-logistic distribution for the
pembrolizumab arm and an exponential distribution for the
vinflunine arm, for time after these points (Fig. 2). For ToT,
Weibull and exponential distributions gave the best fit for
the pembrolizumab and vinflunine arms, respectively.
Results for the base case are presented in Table 2. The
projected discounted direct-treatment costs/per patient
were s98 354 and s28 501 in the pembrolizumab and
vinflunine arms, respectively. We further estimated that
patients treated with pembrolizumab and vinflunine would
experience a mean-discounted life expectancy of 2.40 and
0.73 yr, respectively. Pembrolizumab-treated patients had adiscounted QALY gain of 1.38 QALYs when compared with
vinflunine (1.99 vs 0.61 QALYs).
Cost-effectiveness analysis revealed an overall ICER of
s50 529/QALY gained with pembrolizumab over vinflunine.
ICERs of s81 356/QALY and s71 924/QALY were attained for
pembrolizumab compared with taxanes (paclitaxel or
docetaxel monotherapy) and with the pooled treatment
with paclitaxel, docetaxel, or vinflunine monotherapy.
3.2. Sensitivity analyses
The one-way sensitivity analysis results are presented in
Figure 3. The dose intensity of pembrolizumab, extrapola-
tion of OS for pembrolizumab, and the discount rate for
health outcomes had the greatest impact on ICER values,
while the costs for AEs, terminal care, and subsequent
treatment had the least impact.
Probabilistic sensitivity analysis gave an expected ICER of
s50 845/QALY, suggesting that pembrolizumab has a
99% chance of being cost-effective compared to vinflunine
at a willingness-to-pay threshold of s100 000/QALY [14]
(Supplementary material).
4. Discussion
Treatment of advanced urothelial carcinoma poses significant
clinical and economic burdens on health care systems
[2]. Despite the availability of platinum-based chemotherapy
for advanced urothelial carcinoma, the majority of patients
experience disease progression [23]. Until recently, no globally
accepted SoC was available in the second-line setting. In
KEYNOTE-045, pembrolizumab was superior to chemothera-
py in terms of OS, safety, and quality of life [11,24]. Thus,
pembrolizumab received approval from global regulatory
agencies for the treatment of patients with locally advanced or
metastatic urothelial carcinoma who have previously received
platinum-containing chemotherapy. Our model-based analy-
sis showed that pembrolizumab is projected to be cost-
effective compared with vinflunine among patients in Sweden
when evaluated at a cost-effectiveness threshold of s100 000/
QALY from a Swedish health care perspective [14]. Pembroli-
zumab was also cost-effective when compared with paclitaxel
or docetaxel monotherapy, or the pooled arm for paclitaxel,
docetaxel, or vinflunine monotherapy. In both scenarios,
pembrolizumab had better LYs and QALYs.
Medical costs associated with pembrolizumab were
primarily driven by drug acquisition and disease manage-
ment costs. The total drug acquisition costs for pembroli-
zumab were sensitive to the pembrolizumab treatment
duration. AE-related costs only account for approximately
2% of the non–drug costs for pembrolizumab, compared
with 18% for vinflunine.
An analysis based on Kaplan-Meier curves without RPSFT
adjustment for patients receiving subsequent therapy in the
vinflunine arm revealed a slight increase in the ICER, but
pembrolizumab was still considered cost-effective (Table 2).
Sarfaty et al. [25] recently reported on the cost-
effectiveness of pembrolizumab as second-line therapy
for advanced urothelial carcinoma. However, their study
Fig. 2 – Estimation of overall survival (OS) and progression-free survival (PFS). KM = Kaplan-Meier; KM15 + LogLogistic = KM up to 15 week and log-
logistic model thereafter; KM15 + Exponential = KM up to 15 week and exponential model thereafter; KM32 + LogLogistic = KM up to 32 week and log-
logistic model thereafter; KM32 + Exponential = KM up to 32 week and exponential model thereafter. OS for vinflunine was adjusted using the rank-
preserving structural-failure time method.
Table 2 – Discounted results for the cost-effectiveness of pembrolizumab compared to chemotherapy.
Comparator Total Incremental ICER
Costs (s) LYs QALYs Costs (s) LYs QALYs (s/QALY)
Base case: Pembro vs vinflunine (with RPSFT adjustment)
Vinflunine 28 501 0.73 0.61
Pembrolizumab 98 354 2.40 1.99 69 852 1.66 1.38 50 529
Pembro vs vinflunine (no adjustment)
Vinflunine 28 844 0.76 0.63
Pembro 98 354 2.40 1.99 69 510 1.63 1.36 51 215
Pembro vs paclitaxel/docetaxel/vinflunine (with two-stage adjustment) a
P/D/V 25 054 1.18 0.97
Pembro 98 208 2.40 1.99 73 154 1.22 1.02 71 924
Pembro vs paclitaxel/docetaxel (with two-stage adjustment) a
P/D 25 182 1.33 1.09
Pembro 98 348 2.40 1.99 73 166 1.07 0.90 81 356
ICER = incremental cost-effectiveness ratio; RPSFT = rank-preserving structural failure time; LY = life years; QALY = quality-adjusted life years; P/D/ = paclitaxel/
docetaxel; P/D/V = paclitaxel/docetaxel/vinflunine.
a For the P/D/V and P/D control arms, two-stage adjustment and a log-logistic distribution for fitting of overall survival was the most appropriate technique
according to statistical analysis of the KEYNOTE-045 data. The RPSFT adjustment method was the second best method in this scenario.
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Fig. 3 – Tornado diagram showing the impact of changes in each of the input parameters on the incremental cost-effectiveness ratio (ICER) results.
AE = adverse event; RPSFT = rank-preserving structural failure time; OS = overall survival; PFS = progression-free survival; ToT = time on treatment;
Llogistic = log-logistic. The intercept and log(scale) are estimated parameters for the respective parametric survival models.
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mal modeling methods for survival, utility, and costs
[20,25]. Our analysis has several strengths that explain
the difference in results. We modeled OS and PFS using a
partitioned survival approach that directly uses trial results
to model survival and is commonly applied when evaluating
cost-effectiveness in advanced oncology indications [15]. A
piecewise approach was used for extrapolation, and survival
was adjusted for patients in the control arm who received
immunotherapy after chemotherapy. These analyses
allowed more accurate prediction of OS. We also adopted
a time horizon long enough to capture long-term health
outcomes and costs. This was essential, as the treatment
effect of immunotherapy may last even after discontinua-
tion and lead to long-term survival gains [26]. Our model
uses EQ-5D utility values estimated by health state directly
from KEYNOTE-045 trial. In addition to drug costs,
administration costs, and AE costs as used by Sarfaty
et al. [25], we modeled disease management costs by health
state as well as terminal care costs. Our comparators include
vinflunine, taxanes (paclitaxel and docetaxel), and the
entire KEYNOTE-045 control arm, thus providing a com-
prehensive evaluation of the cost-effectiveness of pem-
brolizumab in comparison to different comparators as
second-line therapy for advanced urothelial carcinoma after
platinum-based chemotherapy.
Overall, pembrolizumab remained cost-effective com-
pared with vinflunine, taxanes (paclitaxel or docetaxel
monotherapy), and with the pooled treatment (paclitaxel,
docetaxel, or vinflunine monotherapy) over several input
parameters as second-line therapy for patients withadvanced urothelial carcinoma who had received plati-
num-based chemotherapy, and experienced disease pro-
gression during or following that chemotherapy. The
evidence for the cost-effectiveness of pembrolizumab for
advanced urothelial carcinoma as observed for Sweden in
our analysis is generally representative of several European
countries with similar health care systems.
4.1. Limitations
Owing to the lack of long-term PFS and OS data,
extrapolations performed in the model make the results
sensitive to distributional assumptions. The model used
statistical methodology and objective criteria recom-
mended by NICE to extrapolate Kaplan-Meier data for OS
and PFS over the time horizon of the model [22]. However,
actual survival rates may differ and long-term follow-up
from clinical trials or real-world data is needed to validate
the results. A sensitivity analysis showed that the model
results are robust to input variations. In addition, the ICER
results are only interpretable for the health system
evaluated in this study or for countries with similar
resource utilization, treatment costs, and AE management
costs. However, the modeling framework and methods used
in this study are generalizable to the other countries.
5. Conclusions
The model results suggest that pembrolizumab improves
survival, increases QALYs, and is cost-effective as second-line
therapycompared with vinflunine for the treatment of locally
E U R O P E A N U R O L O G Y O N C O L O G Y 3 ( 2 0 2 0 ) 6 6 3 – 6 7 0 669advanced metastatic urothelial carcinoma in Swedish adults
who have received prior platinum-containing chemotherapy
at a willingness-to-pay threshold of 100 000 s/QALY gained.
Pembrolizumab is also cost-effective when compared with
paclitaxel or docetaxel monotherapy, and with paclitaxel,
docetaxel, or vinflunine monotherapy.
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